These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 37314801)

  • 1. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
    Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
    Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Fonseca V; Umpierrez GE; Caramori ML; Joseph A; Lambelet M; Lawatscheck R; Bakris GL;
    Diabetes Obes Metab; 2023 Feb; 25(2):407-416. PubMed ID: 36193847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
    Sarafidis P; Agarwal R; Pitt B; Wanner C; Filippatos G; Boletis J; Tuttle KR; Ruilope LM; Rossing P; Toto R; Anker SD; Liu ZH; Joseph A; Ahlers C; Brinker M; Lawatscheck R; Bakris G;
    Clin J Am Soc Nephrol; 2023 May; 18(5):602-612. PubMed ID: 36927680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
    Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
    Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Agarwal R; Tu W; Farjat AE; Farag YMK; Toto R; Kaul S; Lawatscheck R; Rohwedder K; Ruilope LM; Rossing P; Pitt B; Filippatos G; Anker SD; Bakris GL;
    Ann Intern Med; 2023 Dec; 176(12):1606-1616. PubMed ID: 38048573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
    Rossing P; Burgess E; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Gillard P; MacIsaac RJ; Wainstein J; Joseph A; Brinker M; Roessig L; Scott C; Bakris GL;
    Diabetes Care; 2022 Apr; 45(4):888-897. PubMed ID: 35061867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
    Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
    Rosas SE; Ruilope LM; Anker SD; Pitt B; Rossing P; Bonfanti AAC; Correa-Rotter R; González F; Munoz CFJ; Pergola P; Umpierrez GE; Scalise A; Scott C; Lawatscheck R; Joseph A; Bakris GL;
    Kidney Med; 2023 Oct; 5(10):100704. PubMed ID: 37745646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
    Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
    Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
    Flack JM; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Adler SG; Fried L; Jamerson K; Toto R; Brinker M; Farjat AE; Kolkhof P; Lawatscheck R; Joseph A; Bakris GL;
    Kidney Med; 2023 Dec; 5(12):100730. PubMed ID: 38046911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
    Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
    N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
    Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
    Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.